Refractory ventricular fibrillation (RVF) and pulseless ventricular tachycardia (pVT) represent among the most challenging scenarios in resuscitation medicine. Despite the use of repeated defibrillation, standard antiarrhythmic therapy, and epinephrine, these shockable rhythms persist in a significant subset of cardiac arrest patients—and outcomes remain dismal. Accumulating evidence now questions whether epinephrine may be actively perpetuating these arrhythmias through catecholamine-mediated myocardial sensitization, while simultaneously raising the profile of esmolol, an ultra-short-acting beta-1 selective blocker, as a physiologically rational, evidence-supported alternative. This paper examines the case for replacing epinephrine with esmolol in shockable rhythm cardiac arrest algorithms, drawing on emerging systematic review data, prehospital feasibility research, and foundational pharmacological principles.
Introduction
The Advanced Cardiac Life Support (ACLS) shockable rhythm algorithm has remained structurally unchanged for decades: high-quality CPR, sequential defibrillation, and epinephrine 1 mg every three to five minutes, supplemented by antiarrhythmic agents after the third unsuccessful shock. This approach treats ventricular fibrillation and pulseless ventricular tachycardia as conditions requiring vasopressor support to augment coronary perfusion pressure. The logic is physiologically defensible in theory, but mounting clinical and mechanistic evidence suggests it may be profoundly counterproductive in practice. Epinephrine's beta-adrenergic effects lower the threshold for lethal ventricular dysrhythmias, increase myocardial oxygen consumption, and may be actively sustaining the very fibrillation the algorithm seeks to terminate.
Refractory ventricular fibrillation is typically defined as persistent VF despite three defibrillation attempts, three doses of epinephrine 1 mg, and administration of amiodarone. It represents a subset of shockable-rhythm arrest with particularly poor prognosis under current protocols. The pathophysiological driver in many such cases is believed to be an adrenergic surge—endogenous catecholamines released in response to ischemic stress—compounded by exogenous epinephrine administration. This creates an electrophysiologically hostile environment in which the fibrillating myocardium is increasingly resistant to conversion. Against this backdrop, esmolol's pharmacology represents a direct pharmacological counterpoint: by selectively blocking beta-1 adrenergic receptors, it dampens the catecholamine storm, reduces myocardial oxygen demand, and may restore the electrical stability necessary for successful defibrillation.
The Problem with Epinephrine in Shockable Rhythms
Epinephrine's alpha-adrenergic effects increase aortic diastolic pressure and redirect blood flow toward the coronary and cerebral circulations during CPR—an effect that seems beneficial. However, its concurrent beta-adrenergic stimulation lowers the VF threshold, increases right-to-left pulmonary shunting (worsening systemic oxygenation), elevates myocardial oxygen consumption, and sensitizes the myocardium to recurrent arrhythmias both before and after ROSC. In a fibrillating myocardium—already consuming oxygen at rates significantly greater than a perfusing rhythm—this is not a neutral intervention. It is potentially harmful. When epinephrine is administered to a patient whose primary problem is an electrically unstable myocardium driven by catecholamine excess, it is pharmacologically counterintuitive: the clinician is adding fuel to a fire that is already burning.
The PARAMEDIC-2 trial (Perkins et al., 2018), the largest RCT of epinephrine in OHCA, found that while epinephrine marginally improved 30-day survival (NNT = 112), there was no improvement in neurologically intact survival—and a significantly higher rate of severe neurological impairment among epinephrine survivors. Critically, PARAMEDIC-2 did not stratify outcomes by initial rhythm. Subsequent rhythm-specific analyses, including Fanet et al. (2025) and Fernando et al. (2023), have demonstrated that the harm signal for epinephrine is concentrated in patients with shockable rhythms, while non-shockable rhythms (PEA and asystole) may derive modest benefit. This rhythm-specific divergence makes biological sense: VF patients who respond to early defibrillation need no vasopressor; those who don't may be harmed by one.
Pharmacological Rationale for Esmolol in Refractory VF/pVT
Esmolol is an ultra-short-acting, beta-1 selective adrenergic receptor blocker with an elimination half-life of approximately nine minutes, a pharmacokinetic profile ideally suited to the dynamic resuscitation environment. Unlike longer-acting beta-blockers, esmolol's effects dissipate rapidly if hemodynamic compromise arises following ROSC, providing a meaningful safety margin for clinical use. Its mechanism of action in RVF is multifaceted: it suppresses epinephrine-mediated hyperphosphorylation of the ryanodine receptor-2, inhibiting excessive myocardial calcium influx; it reduces the electrical restitution instability that perpetuates fibrillation; it decreases myocardial oxygen consumption; and it may reduce the number of defibrillation attempts required to achieve ROSC. Critically, it directly counters the catecholamine milieu, both endogenous and exogenous, that is central to RVF pathophysiology.
Systematic Review Evidence: Hasegawa et al.
Hasegawa, Sharma, and Im Lee (CHEST, 2023) conducted a systematic review and meta-analysis specifically examining esmolol for refractory VF and pulseless VT—the first comprehensive synthesis of evidence across this literature. Drawing on available observational studies, case series, and earlier foundational work, the review assembled the cumulative evidence base for esmolol in this high-acuity, treatment-resistant population. The findings supported esmolol's association with improved ROSC rates in patients who had failed standard ACLS including defibrillation, epinephrine, and amiodarone. While the authors acknowledged that the current evidence base consists predominantly of observational studies and that randomized controlled trial data remains limited, the directional consistency of the evidence across multiple study designs and settings lends biological plausibility and clinical credibility to esmolol's role. The review's importance lies not only in its findings, but in its framing: it positions esmolol as a legitimate pharmacological candidate for protocol inclusion in refractory shockable rhythm arrest, not merely a rescue anecdote.
Prehospital Feasibility: Patrick et al. (2022)
A critical translational question for any in-hospital intervention is whether it is operationally feasible in the prehospital EMS environment. Patrick and colleagues (J Am Coll Emerg Physicians Open, 2022) directly addressed this at Montgomery County Hospital District EMS in Texas, a high-volume ground-based agency. Following a protocol change on December 10, 2018, that added esmolol 0.5 mg/kg single bolus to the RVF treatment algorithm, 70 RVF patients were identified over the subsequent 18 months. Esmolol was successfully administered in 61 of these patients (87%), exceeding the pre-defined feasibility threshold of 75%. Median time from EMS arrival to drug administration was approximately 17 minutes, consistent with the natural resuscitation timeline following failure of initial defibrillation and epinephrine. Prehospital ROSC was higher in the esmolol group (38%) versus the historical control period (24%), though the difference did not reach statistical significance (p = 0.09), likely due to sample size limitations. Few patients survived to 24 hours or hospital discharge in either group, precluding definitive outcome comparisons. Despite the statistical limitations, this study established two important findings: that prehospital paramedics can reliably identify RVF and administer esmolol with high fidelity, and that the drug's effect on ROSC trends in a clinically meaningful direction. The authors explicitly noted that epinephrine's role in RVF warrants reevaluation, observing that fibrillated myocardium has significantly increased oxygen consumption, which exogenous epinephrine likely worsens via beta-adrenergic stimulation. They concluded that an early esmolol protocol, potentially without exogenous epinephrine, may warrant investigation in patients with shockable rhythms.
Foundational Hospital-Based Evidence
Before systematic review or prehospital data existed, two key hospital-based observational studies established the initial evidence base. Driver et al. (Resuscitation, 2014) reported a retrospective series of RVF patients treated with esmolol (0.5 mg/kg bolus followed by infusion up to 100 mcg/kg/min) after standard ACLS failure, finding improved survival compared to those who did not receive esmolol. Lee et al. (Resuscitation, 2016) conducted a matched cohort study of 55 RVF patients, reporting higher ROSC rates, higher survival to discharge, and improved neurological outcomes in the esmolol group. These studies' effect sizes—while generated from small, non-randomized samples—were striking enough to drive protocol adoption at multiple institutions and directly informed both the Patrick prehospital protocol and the Hasegawa meta-analysis. Case reports including Hwang et al. (BMJ Case Reports, 2019) have further described ROSC achievement with low-dose esmolol in patients who had failed sequential defibrillation including double sequential defibrillation—supporting esmolol's role not as a rescue measure of last resort, but as a targeted pharmacological intervention.
Algorithm Implications and the Path Forward
The convergence of mechanistic rationale, observational hospital data, systematic review synthesis, and prehospital feasibility evidence creates a compelling argument for a substantive change to shockable rhythm algorithms. A rational evidence-based revision might proceed as follows: early aggressive defibrillation remains the cornerstone of therapy; amiodarone or lidocaine are administered per current guidelines after the third unsuccessful shock; epinephrine administration is deferred or omitted in VF/pVT; and esmolol 0.5 mg/kg IV bolus is administered when VF or pVT persists beyond the third defibrillation attempt, potentially followed by a maintenance infusion. This approach directly targets the pathophysiological mechanism of RVF—adrenergic excess and catecholamine-driven arrhythmogenesis—rather than compounding it.
The objection most frequently raised against removing epinephrine from shockable rhythm algorithms is the absence of a large randomized controlled trial demonstrating esmolol's superiority. This is legitimate and the EsiVF and related trials currently underway will be informative. However, clinical equipoise has shifted substantially. The existing evidence for esmolol's benefit is directionally consistent across animal studies, in-hospital observational data, case series, systematic review, and now prehospital protocol data. The evidence that epinephrine is harmful in shockable rhythms is similarly convergent. Waiting for a definitive RCT while continuing to administer a drug with growing evidence of harm in this specific population is itself an ethical question that the resuscitation community must confront.
Conclusion
The question of whether esmolol should replace epinephrine in shockable rhythm cardiac arrest algorithms is no longer hypothetical. The pharmacological case is sound, the clinical signal is consistent, and the prehospital feasibility has been demonstrated. What remains is the courage of guideline committees to act on available evidence rather than wait for certainty that may never arrive in the time required. Refractory ventricular fibrillation is a high-mortality, time-sensitive emergency. The current algorithm may be contributing to the very failure it was designed to prevent. Esmolol offers a mechanism-based, operationally feasible, and evidence-supported alternative that deserves formal inclusion in ACLS shockable rhythm protocols and a prospective randomized trial to confirm what the existing data strongly suggest.
References
- Driver BE, Debaty G, Plummer DW, Smith SW. Use of esmolol after failure of standard cardiopulmonary resuscitation to treat patients with refractory ventricular fibrillation. Resuscitation. 2014;85(10):1337–1341. doi: 10.1016/j.resuscitation.2014.06.032.
- Fanet L, Javaudin F, Dumas F, et al. Association of epinephrine and outcome in cardiac arrest with refractory shockable rhythm: a population-based, propensity-score matched analysis. Crit Care. 2025;29(1):252. doi: 10.1186/s13054-025-05417-4. PMID: 40537836.
- Fernando S, Mathew R, Sadeghirad B, et al. Epinephrine in out-of-hospital cardiac arrest. CHEST. 2023;164(2):381–393. doi: 10.1016/j.chest.2023.01.033.
- Hasegawa D, Sharma A, Im Lee Y. A systematic review and meta-analysis of esmolol for refractory ventricular fibrillation and pulseless ventricular tachycardia. CHEST. 2023;164:A1568.
- Hwang CW, Gamble G, Marchick MR. A case of refractory ventricular fibrillation successfully treated with low-dose esmolol. BMJ Case Rep. 2019;12(3):e228208. doi: 10.1136/bcr-2018-228208.
- Lee YH, Lee KJ, Min YH, et al. Refractory ventricular fibrillation treated with esmolol. Resuscitation. 2016;107:150–155. doi: 10.1016/j.resuscitation.2016.07.243.
- Perkins GD, Ji C, Deakin CD, et al.; PARAMEDIC2 Collaborators. A randomized trial of epinephrine in out-of-hospital cardiac arrest. N Engl J Med. 2018;379(8):711–721. doi: 10.1056/NEJMoa1806842.
- Patrick C, Crowe RP, Ward B, Mohammed A, Keene KR, Dickson R. Feasibility of prehospital esmolol for refractory ventricular fibrillation. J Am Coll Emerg Physicians Open. 2022;3(2):e12700. doi: 10.1002/emp2.12700. PMID: 35425942.
- Raymond K, Wheeler E, Shank M. Traumatic refractory ventricular fibrillation successfully treated with intra-arrest esmolol. Case Rep Acute Med. 2021;4(3):80–84. doi: 10.1159/000518850.